Is Your Patient Eligible?

An estimated 50,000 mCRPC patients each year could benefit from knowing their nuclear AR-V7 status

It's estimated that about 50,000 metastatic castration-resistant prostate cancer (mCRPC) patients each year could benefit from knowing their nuclear AR-V7 status prior to selecting treatment. Advanced prostate cancer patients who become resistant to next generation-hormonal therapies or androgen receptor (AR)-targeted therapies, such as apalutamide, abiraterone, or enzalutamide, may often respond to taxane chemotherapy.1,2,3 The Oncotype DX AR-V7 Nucleus Detect test can help you confidently choose the therapy that will help offer your patients the opportunity for longer overall survival.

Eligibility criteria

The AR-V7 Nucleus Detect assay is ideal for patients who:

  • Have confirmed mCRPC
  • Have received and failed AR-targeted therapy
  • Are considering additional AR-targeted therapies

When to order the AR-V7 Nucleus Detect test

Ordering the AR-V7 Nucleus Detect test is appropriate for mCRPC patients who have failed an AR-targeted therapy like apulatamide (Erleada®), abiraterone (Zytiga®), and enzalutamide (Xtandi®).

Why order the test after failure on AR-targeted therapy

Although AR-targeted therapies are a breakthrough in mCRPC treatment, it’s important to remember that some patients never respond to AR-targeted therapies and many patients who initially respond to AR-targeted therapies develop acquired resistance to them over time.4

The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to a line of therapy, including AR targeted therapies5:

  • Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving one round of therapy
  • Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of therapy.

The percentage of mCRPC patients with the AR splice variant -7 (AR-V7+) increased with continued treatment exposure5

AR Resistance Graph
Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.

REFERENCES

1. Antonarakis et al. N Engl J Med. 2014.
2. Scher et al. Eur Urol. 2016.
3. Antonarakis et al. JAMA Oncol. 2015.
4. Antonarakis et al. Expert Rev Anticancer Ther. 2015.
5. Scher et al. JAMA Oncol. 2016.
6. Scher et al. JAMA Oncol. 2018.

 

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

 Contact Us
Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.®
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.